Table 1.
Characteristics of the statin users and non-users (N=2007)
| Variables | Statin users (N=525) | Non-users (N=1482) | p Value |
|---|---|---|---|
| Mean Age | 66.7±10.8 | 62.4±13.3 | <0.0001 |
| Male | 309 (58.9%) | 1046 (70.6%) | <0.0001 |
| Previous MI | 202 (38.5%) | 111 (7.5%) | <0.0001 |
| Peripheral arterial disease | 8 (1.5%) | 9 (0.6%) | 0.13 |
| Congestive heart failure | 164 (31.2%) | 100 (6.7%) | <0.0001 |
| Ischaemic stroke | 61 (11.6%) | 66 (3.8%) | <0.0001 |
| Diabetes | 322 (61.3%) | 696 (47%) | <0.0001 |
| Hypertension | 436 (83.0%) | 759 (51.2%) | <0.0001 |
| Dysrhythmia | 28 (5.3%) | 40 (2.7%) | 0.02 |
| Chronic renal failure | 115 (21.9%) | 78 (5.3%) | <0.0001 |
| Current smoker | 72 (13.7%) | 572 (38.6%) | <0.0001 |
| Medications used prior to the hospitalisation | |||
| Aspirin | 386 (73.5%) | 170 (11.5%) | <0.0001 |
| Clopidogrel | 122 (23.2%) | 29 (2.0%) | <0.0001 |
| β Blocker | 264 (50.3%) | 138 (9.3%) | <0.0001 |
| ACEI | 191 (36.4%) | 114 (7.7%) | <0.0001 |
| Antiarrhythmic agent | 8 (1.5%) | 5 (0.3%) | 0.004 |
| Type of MI | <0.0001 | ||
| STEMI | 151 (28.8%) | 951 (64.2%) | |
| NSTEMI | 258 (49.1%) | 406 (27.4%) | |
| Unstable angina | 116 (22.1%) | 125 (8.4%) | |
| Heart rate (beats/min) | 85.4±23.2 | 82.3±24.7 | 0.02 |
| Systolic blood pressure (mm Hg) | 135.6±35.8 | 127.2±34.7 | <0.0001 |
| Diastolic blood pressure (mm Hg) | 78.9±20.7 | 75.8±21.5 | 0.005 |
| Troponin T (ng/ml) | 1.56±3.7 | 2.79±5.4 | <0.0001 |
| CKMB (ng/ml) | 46.7±89 | 109.3±156 | <0.0001 |
| Ejection fraction (%) | 49.2±15 | 48.7±14 | 0.68 |
| Medications used during the hospitalisation | |||
| Aspirin | 517 (98.5%) | 1465 (98.9%) | 0.504 |
| Clopidogrel | 399 (76.0%) | 1173 (79.1%) | 0.132 |
| β Blocker | 275 (52.4%) | 741 (50%) | 0.361 |
| ACEI | 262 (49.9%) | 782 (52.7%) | 0.2647 |
| Antiarrhythmic agent | 52 (9.9%) | 146 (9.9%) | 0.972 |
| Thrombolytics Administered | 41 (7.8%) | 433 (29.22%) | <0.0001 |
| PCI performed | 148 (28.2%) | 520 (35.1%) | 0.004 |
| CABG | 25 (4.8%) | 37 (2.5%) | 0.01 |
ACEI, ACE inhibitors; CABG, coronary artery bypass graft; CKMB, creatine kinase MB isoenzyme; MI, myocardial infarction; NSTEMI, non-ST segment elevation MI; PCI, percutaneous coronary intervention; STEMI, ST segment elevation MI.